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BACKGROUND: Obesity has been inconsistently linked to prostate cancer, mainly with mortality rather than incidence. Few large-scale
studies exist assessing obesity in relation to prostate-specific antigen (PSA)-detected prostate cancer.
METHODS: We used cases and stratum-matched controls from the population-based PSA-testing phase of the Prostate testing for
cancer and Treatment study to examine the hypothesis that obesity as measured by body mass index (BMI), waist circumference and
waist-to-hip ratio (WHR) is associated with increased prostate cancer risk, and with higher tumour stage and grade. In all, 2167
eligible cases and 11638 randomly selected eligible controls with PSA values were recruited between 2001 and 2008. A maximum of
960 cases and 4156 controls had measurement data, and also complete data on age and family history, and were included in the final
analysis. BMI was categorised as o25.0, 25.0–29.9, X30.0 in kgm
 2.
RESULTS: Following adjustment for age and family history of prostate cancer, we found little evidence that BMI was associated with
total prostate cancer (odds ratio (OR): 0.83, 95% confidence interval (CI): 0.67, 1.03; highest vs lowest tertile; P-trend 0.1). A weak
inverse association was evident for low-grade (OR: 0.76, 95% CI: 0.59, 0.97; highest vs lowest tertile; P-trend 0.045) prostate cancer.
We found no association of either waist circumference (OR: 0.94, 95% CI: 0.80, 1.12; highest vs lowest tertile) or waist-to-hip ratio
(WHR; OR: 0.93, 95% CI: 0.77, 1.11; highest vs lowest tertile) with total prostate cancer, and in analyses stratified by disease stage
(all P-trend40.35) or grade (all P-trend40.16).
CONCLUSION: General adiposity, as measured by BMI, was associated with a decreased risk of low-grade PSA-detected prostate
cancer. However, effects were small and the confidence intervals had limits very close to one. Abdominal obesity (as measured by
WHR/waist circumference) was not associated with PSA-detected prostate cancer.
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Obesity is associated with a number of chronic diseases, including
coronary artery disease, hypertension, diabetes and some cancers
(Rodriguez et al, 2001; Calle et al, 2003). The association of obesity
with hormone-related cancers, such as prostate cancer, has been
inconsistent in epidemiological studies. Obesity has been more
strongly positively associated with prostate cancer mortality rather
than showing consistent associations with incidence (Andersson
et al, 1997; Rodriguez et al, 2001; Calle et al, 2003; Wright et al,
2007). Studies examining obesity during prostate development in
earlier life, and its possible effect on prostate cancer development
later, have also produced contradictory results (Giovannucci et al,
1997; Schuurman et al, 2000). Overall, there are studies showing
positive (Gronberg et al, 1996; Veierod et al, 1997; Putnam et al,
2000), null (Whittemore et al, 1995; Giovannucci et al, 1997;
Nilsen and Vatten, 1999; Habel et al, 2000; Lee et al, 2001; Jonsson
et al, 2003; Gallina et al, 2007) and inverse (Giovannucci et al,
2003; Wright et al, 2007) associations between body mass index
(BMI) and prostate cancer risk.
The inconsistency between these studies might be attributed
to a possible interaction between obesity and factors such as age,
or to differential effects of obesity on low-grade and high-grade
cancer implying aetiological heterogeneity for different tumour
subtypes (Freedland et al, 2006). In addition, many studies do not
distinguish between central and peripheral adiposity.
There is some evidence, from prospective studies, that obesity is
associated with a reduction in risk of incident prostate cancer
(Giovannucci et al, 2003; Wright et al, 2007). There are biological
mechanisms which may explain potential protective effects against
initiation of prostate cancer (Giovannucci et al, 2003). For
example, there tend to be lower circulating levels of testosterone
in obese compared with non-obese men (Pasquali et al, 1991;
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yField et al, 1994). Observed protective effects may also be an
artefact of haemodilution of prostate-specific antigen (PSA) values
in larger men, thereby reducing PSA threshold-based detection of
true cancers by misclassifying them as non-cancers (Grubb et al,
2009).
In two case–control studies (Hsing et al, 2000; von Hafe et al,
2004), central adiposity was associated with an increased risk of
prostate cancer progression. However, the risk was increased for
non-advanced stage as well. Most central adiposity case–control
and prospective studies did not show any associations when BMI
was assessed (Hsing et al, 2000; Lee et al, 2001; von Hafe et al,
2004) and Giovannucci et al (1997), in their prospective cohort
study, showed no association between either adult BMI or waist-
to-hip ratio (WHR) and risk of total or advanced prostate cancer
(Giovannucci et al, 1997). One prospective cohort study (MacInnis
et al, 2003) found no overall association with prostate cancer, but
modest associations with the risk of aggressive disease, whereas
other studies of the same type (Hubbard et al, 2004) report an
overall increased risk with increasing WHR.
We conducted a case–control study nested within the
PSA-testing phase of the Prostate testing for cancer and Treatment
(ProtecT) study (Donovan et al, 2002) to examine associations of
obesity with screen-detected prostate cancer. The measures of
obesity included BMI, waist circumference and WHR. Associations
with obesity were examined for total prostate cancer as well as
its subtypes (localised, advanced; high-grade, intermediate grade
and low grade).
PARTICIPANTS AND METHODS
The methodology of the ProtecT study has been described
previously (Donovan et al, 2002). ProtecT is an ongoing
randomized controlled trial that will compare the effectiveness
and acceptability of treatments for localised prostate cancer in men
aged 50–69 years. Between 2001 and 2008, over 110000 men aged
50–69 years, from B300 primary care centres (general practises)
across the United Kingdom, attended prostate check clinics, where
histologically confirmed prostate cancer cases were identified
through a combination PSA testing, digital rectal examination
(DRE) and 10-core transrectal ultrasound-guided biopsy (the latter
two investigations only apply to those with PSA X3). Repeat
biopsies were offered to men with a normal initial biopsy, in whom
there was a high index of clinical suspicion (evidence of high-grade
prostatic intraepithelial neoplasia or suspicious features on initial
biopsy) or in whom PSA concentration was persistently elevated.
Tumours were staged using the TNM staging system. A central
pathology review is also conducted.
Selection of cases and controls
Cases were men aged 50–69 years, who underwent PSA measure-
ment and had a histological diagnosis of primary prostate cancer.
We defined localised cancer as T1–T2, NX or NO, MX or MO and
advanced cancer as T3–T4 or N1 or M1; there were 1894 localised
cases and 257 advanced cases (not taking account of the avail-
ability or not of anthropometric measurements). We defined high-
grade cancer as Gleason grades 8–9; intermediate grade cancer as
Gleason grade 7; and low-grade cancer as Gleason grade p6.
All participants with no evidence of prostate cancer after PSA
testing, DRE and/or biopsy were eligible to be controls. Controls
were stratum matched to cases by age (5-year bands), and the
primary care centres from which they were recruited. The index
date for controls was the date of the prostate check clinic. Such
matching automatically matches for calendar time, as prostate
check clinics were completed sequentially. Detailed descriptions
of ProtecT and the protocol for nested case–control selection are
published elsewhere (Zuccolo et al, 2008).
Exposure assessment
Obesity indicators were measured as well as self-reported. The
measured weight value was taken at the prostate check clinic
appointment by clinical staff. The weight was recorded, and it was
explained to the participant that general health measurements
were taken in order to examine the links with prostate cancer. The
participant was weighed to the nearest 0.1kg, and the measure-
ment was noted by the clinical staff.
Participants were given a self-completion diet, health and
lifestyle questionnaire at the clinic; this included questions on
body size and weight in stones/pounds, height in feet/inches, and
inside leg measurement in inches. They were also provided with
a tape measure with which to take waist and hip measurements
themselves and return it together with the questionnaire.
Participants were instructed regarding the use and placement of
the tape measure in order to make the measurements. Each tape
measurement (in inches) was marked with a single line on the
tape measure, labelled with the relevant letter (W or H) (measured
value) and also recorded in the relevant questionnaire box by the
participant (self-reported measurement).
We used a metric based on both available measurements,
derived from the measured value if that was available and the self-
reported value otherwise. BMI was derived from weight and height
measurements as kgm
 2; WHR was computed as waist circum-
ference divided by hip circumference.
In November 2008, there were 2167 prostate cancer cases and
11638 controls, randomly selected from B100000 men not
diagnosed with prostate cancer. The data composition of the stage
and grade analyses is present in Table 1a. Data on BMI could be
derived for 4769 controls and 1025 cases; data on WHR could be
derived for 4917 controls and 1075 cases, whereas waist
circumference data were available for 5020 controls and 1089
cases (Table 1a). Subjects included in the final BMI analyses
had complete data on BMI, age and family history, and comprised
3931 controls and 919 cases. For the final analyses for waist
circumference, 4156 controls and 960 cases had complete data on
waist circumference, age and family history. For the final WHR
analyses there were 4069 controls and 948 cases with complete data
on WHR, age and family history (analyses presented in Table 2).
The study received ethical approval from Trent Multicentre
Research and Ethics Committee and all participants provided
written informed consent.
Statistical analysis
BMI was categorised according to the WHO suggestions using
categories o25.0, 25.0–29.9, X30.0 in kgm
 2 (Expert panel on the
identification evaluation and treatment of overweight and obesity
in adults, 1998). Waist circumference and WHR were categorised
into tertiles based on the distribution of these measures amongst
controls, as follows: waist circumference (p91.4, 91.5–99.1,
499.1cm) and WHR (o0.91, 0.91–0.95, 40.95).
Conditional logistic regression was used to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) for associations of
obesity with total prostate cancer. We computed two models. First,
the basic conditional logistic regression model, in which the
stratum matching of cases to controls by age and recruitment
centre is taken into account. The second multivariable model was
additionally adjusted for exact age at prostate check clinic and
family history, as these are the established risk factors for prostate
cancer.
The ORs for associations with advanced and localised cancer vs
controls and for low, intermediate and high-grade disease vs
controls were compared using a multinomial logistic regression
model. This model provides a statistical test for heterogeneity
in ORs comparing associations of the obesity indicators with
localised vs advanced prostate cancers, but it is unconditional;
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the study centre where the recruiting general practice was based
(nine-level variable).
The maximum number (1089 cases and 5020 controls) of
subjects used in the analysis, before adjusting for other factors, was
compared with the eligible participants not included in the analysis
(1078 prostate cancer cases and 6618 randomly selected controls)
using t-tests for continuous variables and the w
2-test for binary
response variables.
The PSA detection bias
Some previous studies have shown a decreased PSA level with
increasing adiposity (Baillargeon et al, 2005; Werny et al, 2007).
This suggests that there could be differential prostate cancer
detection with respect to obesity, particularly for screen-detected
case finding by PSA-based thresholds for biopsy. Therefore, to
assess the potential for PSA detection bias, associations of the
adiposity measures with serum PSA concentration amongst
controls were investigated using linear regression performed on
log-transformed PSA concentrations, adjusted for exact age and
recruitment centre.
Analyses were conducted using Stata/IC 10.1 for Windows
(StataCorp, 2007, College Station, TX, USA).
RESULTS
Table 1b presents the baseline characteristics of the maximum
number of cases and controls with adiposity data (1089 cases and
Table 1a Composition of BMI, waist circumference and WHR data
Derived
BMI data
Available waist
circumference data
Derived
WHR data
Controls 4769 5020 4917
Cases stage and grade
Stage
Localised cases 919 970 957
Advanced cases 100 111 110
Unstaged cases 6 8 8
Grade
Low 691 736 723
Intermediate 272 288 287
High 57 59 59
Ungraded cases 5 6 6
Subjects with complete data on each of BMI, waist circumference,
WHR and factors (age, family history) in final stage and grade
analyses
BMI +
factors
Waist circumference +
factors
WHR +
factors
Controls 4368 4583 4490
Cases stage and grade
Stage
Localised cases 843 882 870
Advanced cases 86 88 88
Grade
Low 632 665 654
Intermediate 242 248 247
High 55 57 57
Abbreviations: BMI¼body mass index; WHR¼waist-to-hip ratio. The derived
metric is defined as the measured value if available and the self-reported value
otherwise. BMI was derived from weight and height measurements as kgm
 2;
WHR was computed as waist circumference divided by hip circumference.
Table 1b Baseline characteristics of cases and controls
Case Control
Variable n Mean (s.d.) % n Mean (s.d.) %
Age at prostate
check clinic
1089 62.3 (5.0) 5013 62.1 (5.0)
Missing 0 0.0 7 0.1
Height (m) 1078 1.76 (0.07) 4976 1.76 (0.07)
Missing 11 1.0 44 0.9
Ethnicity
White 1055 96.9 4927 98.1
Other 2 1.1 48 1.0
Missing 22 2.0 45 0.9
Social class
Working 345 31.7 1560 31.1
Intermediate 131 12.0 583 11.6
Professional 370 34.0 1722 34.3
Missing 243 22.3 1155 23.0
Family history in first degree relatives
Yes 88 8.1 259 5.2
No 888 81.5 4330 86.2
Missing 113 10.4 431 8.6
PSA at PCC (ngml
 1) 1089 8.85 (28.1) 5020 1.40 (1.4)
Missing 0 0.0 0 0.0
Stage
Localised 970 89.1
Advanced 111 10.2 — —
Missing 8 0.7
Grade
Low 736 67.6
Intermediate 288 26.4
High 59 5.4 — —
Missing 6 0.6
Abbreviations: PCC¼prostate check clinic; PSA¼prostate-specific antigen.
Table 2 Association of obesity measures with prostate cancer
Case Control
OR (CI) for basic
model, significance
a
Adjusted
OR (CI)
b
BMI (kgm
 2)
o25.0 264 1080 1.00 1.00
25.0–29.9 481 1996 0.97 (0.82, 1.15) 0.98 (0.82, 1.16)
X30.0 174 855 0.82 (0.66, 1.02) 0.83 (0.67, 1.03)
Trend P-value 0.083 0.097
Waist (cm)
p91.4 385 1615 1.00 1.00
91.5–99.1 286 1217 1.01 (0.85, 1.19) 1.01 (0.85, 1.20)
499.1 289 1324 0.94 (0.79, 1.12) 0.94 (0.80, 1.12)
Trend P-value 0.496 0.517
Waist/hip ratio
p0.908 318 1369 1.00 1.00
0.909–0.952 328 1312 1.09 (0.91, 1.30) 1.09 (0.91, 1.30)
40.952 302 1388 0.92 (0.77, 1.10) 0.93 (0.77, 1.11)
Trend P-value 0.368 0.395
Abbreviations: BMI¼body mass index; CI¼confidence interval; OR¼odds ratio.
aTaking account of the matching variables age (in 5-year bands) and recruitment
centre.
bAdditional adjustment for age and family history. BMI groupings according to
the World Health Organisation suggested categorisations. Ethnicity not controlled for
because of the very small percentage (1%) of non-white participants.
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(5.2%) reported a family history of prostate cancer in first degree
relatives. In the highest tertiles, there were 18.4% cases and 21.5%
controls with BMI X30.0kgm
 2; the percentage of cases with
499cm waist circumference was 30.5%, whereas that of controls
was 32.1%; 31.8% of cases and 33.9% of controls had a WHR
40.95.
The percentage of potentially eligible cases (2167) with missing
BMI information was 52.7%; the respective percentage for
potentially eligible controls (11638) was 59%. The percentages
for missing data on waist measurements were 49.8% for cases
and 56.9% for controls. For 50.4% of cases and 57.8% of controls
information on WHR could not be derived. The maximum
number (1089 cases and 5020 controls) of subjects used in the
analysis, before adjusting for other factors, was similar to the
eligible participants not included in the analysis (1078 prostate
cancer cases and 6618 randomly selected controls) in terms
of family history of prostate cancer in 1st degree relatives
(w
2 P-value¼0.100), but not in terms of age (P-value from
t-test o0.001). Those included in the analysis were on average
a year older than those not included.
Table 2 presents the association of the adiposity measures
BMI, waist measurement and WHR with total prostate cancer.
There was no evidence of any important relationship between any
of the measures of adiposity and total prostate cancer.
To examine the association of the obesity measures with stage
of prostate cancer, we calculated the ORs and CIs for the categories
of BMI/waist circumference/WHR. These are shown in Table 3.
Table 3 Associations of BMI, waist circumference and WHR with prostate cancer stage
Reference group
Stage
Controls Localised OR (CI) Advanced OR (CI) P for heterogeneity
BMI
o25.0 1178 239 1.00 27 1.00
25.0–29.9 2219 448 1.00 (0.84–1.19) 39 0.77 (0.47–1.27)
X30.0 971 156 0.79 (0.63–0.98) 20 0.94 (0.52–1.69)
Trend P-value 0.053 0.745 0.74
Waist (cm)
p91.4 1781 352 1.00 36 1.00
91.5–99.1 1337 265 1.00 (0.84–1.19) 25 0.90 (0.54–1.51)
499.1 1465 265 0.91 (0.77–1.09) 27 0.89 (0.54–1.48)
Trend P-value 0.355 0.585 0.82
WHR
p0.908 1514 291 1.00 28 1.00
0.909–0.952 1437 303 1.10 (0.92–1.31) 28 1.06 (0.62–1.80)
40.952 1539 276 0.93 (0.78–1.11) 32 1.14 (0.68–1.90)
Trend P-value 0.473 0.681 0.53
Abbreviations: BMI¼body mass index; CI¼confidence interval; OR¼odds ratio; WHR¼waist-to-hip ratio. Multinomial logistic regression model adjusted for age, survey
centre, family history. All expected cell frequencies 45. Groupings according to the WHO categorisation for BMI, and according to the distribution of controls for waist
and WHR.
Table 4 Associations of BMI, waist circumference and WHR with grade of prostate cancer (high: Gleason grades 8–9; intermediate: Gleason grade 7;
low: Gleason grade p6)
Reference group
Grade
Controls Low OR (CI) Intermediate OR (CI) High OR (CI) P for heterogeneity
BMI
o25.0 1178 184 1.00 67 1.00 15 1.00
25.0–29.9 2219 331 0.95 (0.78–1.16) 129 1.04 (0.76–1.40) 27 0.99 (0.52–1.87)
X30.0 971 117 0.76 (0.59–0.97) 46 0.85 (0.58–1.25) 13 1.12 (0.53–2.38)
Trend P-value 0.045 0.444 0.822 0.67
Waist (cm)
p91.4 1781 270 1.00 95 1.00 22 1.00
91.5–99.1 1337 199 0.98 (0.81–1.20) 74 1.02 (0.75–1.40) 17 0.99 (0.52–1.88)
499.1 1465 196 0.88 (0.72–1.07) 79 1.00 (0.74–1.36) 18 0.96 (0.51–1.80)
Trend P-value 0.254 0.989 0.909 0.81
WHR
p0.908 1514 212 1.00 86 1.00 23 1.00
0.909–0.952 1437 222 1.10 (0.90–1.35) 89 1.11 (0.82–1.51) 19 0.85 (0.46–1.58)
40.952 1539 220 1.01 (0.83–1.24) 72 0.84 (0.61–1.16) 15 0.64 (0.33–1.23)
Trend P-value 0.812 0.241 0.169 0.24
Abbreviations: BMI¼body mass index; CI¼confidence interval; OR¼odds ratio; WHR¼waist-to-hip ratio. Multinomial logistic regression model adjusted for age, survey
centre, family history. All expected cell frequencies 45. Groupings according to the World Health Organisation categorisation for BMI, and according to the distribution of
controls for waist and WHR.
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history and recruitment centre, the smallest P-value for BMI was
marginal and limited to localised prostate cancer (0.053). Results
were similar for the basic model, adjusted for exact age and survey
centre (not shown). Further data on age, family history and other
medical conditions such as diabetes and cardiovascular disease are
shown in the Supplementary Material.
Results in Table 4 are ORs for the categories of BMI, waist
circumference and WHR, in order to examine the association of
obesity with grade of prostate cancer. For the fully adjusted model
for BMI, we observed a weak association with prostate cancer
grade, limited to the low-grade group (P-trend 0.045; highest vs
lowest tertile OR: 0.76, 95% CI: 0.59, 0.97), with the effect being
small and the respective CI close to 1. Results for the basic model
were largely similar and are not presented.
We did not observe any associations with either waist circum-
ference or WHR after adjusting for age, family history and study
centre for disease stage (all P40.35) or grade (all P40.16).
Amongst controls, the geometric mean PSA values for BMI
categories (o25.0, 25.0–29.9, X30.0kgm
 2) were 1.11 (1.07, 1.16),
1.04 (1.01, 1.07), 0.95 (0.90, 0.99) in ngml
 1, respectively (P-value
o0.001 for highest vs lowest group). Defining L as the lowest
group, M as the middle group and H as the highest group, the
percent differences in means were between L and M 6.3%, between
M and H 8.6%, and between L and H 14.4%. The geometric mean
PSA values for waist measurement categories (o91.5, 91.5–99,
499cm) were 1.08 (1.04, 1.11), 1.06 (1.02, 1.10), 0.96 (0.92, 1.00)
in ngml
 1, respectively (P-value o0.001 for highest vs lowest
group). The percent differences in means were between L and M
1.8%, between M and H 9.4%, and between L and H 11.1%.
The geometric mean PSA values for WHR categories (o0.91,
0.91–0.95, 40.95) were 1.04 (1.00, 1.08), 1.06 (1.02, 1.10), 1.00
(0.96, 1.03) in ngml
 1, respectively (P-value 0.06, for highest vs
lowest group). The percent differences in means were between
L and M 1.9%, between M and H 5.6%, and between L and H 3.8%.
In a sensitivity analysis, we compared different sources of
measurement for weight, waist and hip – as well as the derived
WHR. Comparison was between measured and self-reported
values. Measured and self-reported weight had a Spearman
correlation coefficient of 0.98 (significance level 0.01). The
correlation coefficient for measured and self-reported waist
circumference was 0.99 (significance level 0.01). For measured
and self-reported hip measurements the correlation coefficient was
0.98 (significance level 0.01). Therefore, it is unlikely that using
different sources of measurement introduces bias.
DISCUSSION
We found no evidence that our measures of central adiposity were
associated with PSA-detected prostate cancer. There was only weak
evidence that general adiposity was associated with decreased risk
of low-grade prostate cancer.
Most studies use BMI as a measure of obesity, although BMI
cannot distinguish between lean and fat mass. This can be
problematic for measurement and might account for contradictory
results from several retrospective and prospective cohort studies
using BMI to evaluate adiposity (Andersson et al, 1997; Nilsen and
Vatten, 1999; Rodriguez et al, 2001; Calle et al, 2003; Giovannucci
et al, 2003; Jonsson et al, 2003). Therefore, we used additional
indicators, that is, waist measurements and WHR as estimates of
central adiposity and excess abdominal fat (Arner, 1997). Measures
of central adiposity are also better suited for measurements in
middle-aged men. Abdominal obesity has been linked to several
chronic conditions through mechanisms involving hormonal and
metabolic changes (Kaaks and Stattin, 2010). However, very few
studies (Giovannucci et al, 1997; Hsing et al, 2000; Lee et al, 2001;
MacInnis et al, 2003; Hubbard et al, 2004; von Hafe et al, 2004;
Wallstrom et al, 2009) have examined prostate cancer associations
with abdominal adiposity; prospective cohort and case–control
studies have shown increased risk with increasing WHR but
no association with BMI (Hsing et al, 2000; von Hafe et al, 2004).
This might imply that abdominal fat rather than general obesity
may be associated with prostate cancer risk.
Associations reported in individual studies and for certain
subgroups of men have not been seen consistently across studies.
Obesity (as defined by BMI 430kgm
 2) has been linked with
increased risk in some cohort studies (Lew and Garfinkel, 1979;
Snowdon et al, 1984; Chyou et al, 1994), but not in some
other cohort and case–control studies (Kolonel et al, 1988; Mills
et al, 1989; Nomura and Kolonel, 1991; Kolonel, 1996; Andersson
et al, 1997; Nomura, 2001; Friedenreich et al, 2004). Giovannucci
et al (2003), in their prospective cohort study, reported inverse
associations between BMI and prostate cancer risk in younger men
or those with a family history. Rohrmann et al (2003) observed a
reduced risk of high-grade disease in those with a family history,
but an increased risk of high-grade disease in obese men o50
years old, in a case–control study. Two cohort studies of general
(Engeland et al, 2003) and central (Wallstrom et al, 2009) obesity
found increased risks in younger obese men.
Some hormonal and metabolic alterations that occur in obesity,
such as decreased testosterone, may decrease prostate cancer
risk; however, other alterations such as high insulin, insulin-like
growth factor 1 (IGF-1) and/or leptin levels (Frystyk et al, 1995)
have mitogenic effects (McKeehan et al, 1984) and can potentially
increase risk by promoting prostate cancer progression (Yu and
Rohan, 2000; Chan et al, 2002; Jenks, 2010). Testosterone is
involved in prostatic growth and low levels prevent proliferation
in the prostate; therefore, decreased testosterone in obese men may
explain a protective effect of obesity against incident prostate
cancer. At the same time, high testosterone helps maintain
differentiation in prostatic epithelium, thus, preventing tumour
progression, which means that the low testosterone levels in obese
men increase the risk of tumours that are poorly differentiated/
high grade. The IGF-1 is involved in androgen-independent
progression of prostate cancer and leptin induces migration in
prostate cancer cells, thus obesity-induced hormonal changes may
promote tumour progression (Amling et al, 2004; Freedland et al,
2004). Leptin and insulin/IGF-1 are high in obese men (Hoda et al,
2010) and suppress androgen levels, moreover leptin has been
implicated in advanced and high-grade prostate cancer in two
case–control studies (Saglam et al, 2003; Ribeiro et al, 2006).
Therefore, the simultaneous presence of high insulin and leptin
levels and low testosterone levels explains the reduced risk of
incident tumours, but the increased risk of progression in existing
prostate cancer tumours.
One of the reasons why obesity has been hypothesised to be
associated with greater risk of prostate cancer progression in
case–control, cohort and prospective studies (Andersson
et al, 1997; Putnam et al, 2000; MacInnis et al, 2003; Dal Maso
et al, 2004; Baillargeon et al, 2005; Freedland et al, 2005; Wright
et al, 2007; Gross et al, 2009), as opposed to initiation
(Giovannucci et al, 2003), is that obese men tend to have higher
oestradiol and lower testosterone levels, which have been
associated with more advanced and poorly differentiated tumours
(Hsing et al, 2002; Massengill et al, 2003; Platz et al, 2005) as
explained above. This implies that different associations of obesity
might be observed for prostate cancers of different stage or grade.
Evidence from prospective studies is beginning to show that
energy intake in excess of expenditure, captured by a higher
BMI, may affect prostate carcinogenesis and, in particular, risk of
advanced disease, and that energy imbalance may function late in
the carcinogenic pathway, therefore, facilitating progression rather
than initiation of prostate tumours (Rodriguez et al, 2007).
The differences in risk trends in previous studies, mentioned
above, are possibly because of different methods used for assessing
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prostate cancer stages and grades (Gong et al, 2006; MacInnis and
English, 2006; Littman et al, 2007; Rodriguez et al, 2007). Prostate
cancer has a long natural history, and it might be that BMI in
earlier life is more important for the development of prostate
cancer than adult BMI, explaining the absence of strong
associations with BMI in most studies including the present study.
We do not consider differences in PSA values by BMI to be an
important source of bias. For BMI, as well as the other adiposity
measures, there was weak evidence that PSA levels were linked to
obesity, as the absolute difference between the geometric mean
PSA values in the highest and lowest categories did not exceed
0.16ngml
 1, and the maximum percent difference in means
between BMI categories was 14.4%.
The strengths of the study are its large sample size and a well-
characterised population. In addition, the collection of both self-
reported and clinically measured values for the assessment of the
adiposity indicators used allows assessment of bias from different
sources of measurement. We found no such bias in this study.
However, BMI values could be derived from only 47% of cases
and 42% of the total population. Waist circumference and
WHR measurements had similarly low percentages. For all obesity
variables, the percentage of cases with available information
was higher than the respective percentage of controls. The
reductions in sample size may have affected the power of the
study to detect effects, and it is theoretically possible that
associations may have differed in those included in the analysis
compared to those who could not be included (selection bias).
These are two study limitations, although the study remains large.
Our results do not support the hypothesis that obesity is involved
in prostate cancer progression, although our study is limited to
PSA-detected disease.
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